AEOLUS PHARMACEUTICALS INC

As of June 30, 2017, AEOLUS PHARMACEUTICALS INC carries a market capitalization of 13.81M, placing it among publicly traded companies globally. Its enterprise value stands at 13.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2017, AEOLUS PHARMACEUTICALS INC has 152.09M shares outstanding.

These figures are as of June 30, 2017. The price-to-sales ratio is 17.91, and the price-to-book ratio stands at 66.73.

These figures are as of June 30, 2017. The EV/Sales ratio of 17.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.41M versus a market cap of 13.81M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2017, AEOLUS PHARMACEUTICALS INC maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2017, AEOLUS PHARMACEUTICALS INC posted a negative return on equity (ROE) of -186.43, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -144.49, reflecting losses generated across the asset base. The company generates approximately 192,750.00 in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers.

As of the close on August 24, 2026, AEOLUS PHARMACEUTICALS INC's stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended June 30, 2017, AEOLUS PHARMACEUTICALS INC generated 771,000.00 in revenue and converted that into -4.09M in net income, yielding earnings per share of -0.03. EBITDA reached -4.09M, while operating income came in at -4.09M.

These figures are as of June 30, 2017. Total book value stands at 207,000.00, with working capital of 175,000.00 providing operational flexibility.

AEOLUS PHARMACEUTICALS INC produced -3.35M in operating cash flow over the twelve months ended June 30, 2017.

These figures cover the twelve months ended June 30, 2017. The operating margin of -531.00 and net profit margin of -531.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2017. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -24.28: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AEOLUS PHARMACEUTICALS INC shareholders.

AEOLUS PHARMACEUTICALS INC's most recent stock split took place on July 16, 2004 with a 10:1 split ratio.

As of June 30, 2017, AEOLUS PHARMACEUTICALS INC has an Altman Z-Score of -342.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.